トランスレーショナル医療
オープンアクセス
ISSN: 2161-1025
ISSN: 2161-1025
Wei-Dong Han
Patients with relapsed or refractory Non-Hodgkin lymphoma (NHL) make sure a dismal prediction. Chimeric antigen receptor (CAR) modified T cells targeting CD20 have shown activity in clinical test phase I clinical trial for patients with advanced B-cell lymphomas. We performed a phase IIa trial to further assess the security and efficacy of administering autologous anti-CD20 CAR T (CART-20) cells to patients with refractory or relapsed CD20+ Bcell lymphoma. Eleven (11) patients comprising one with previous auto-HSCT and one primary cutaneous B-cell lymphomas were enrolled. Seven (7) patients experienced cytoreductive chemotherapy for tumor debulking and lymphocyte depletion before T cell potions. CART-20 cells were infused into patients at doses of 2.8 to 14.6×106 cells/kg. The general objective response rate was 9 of 11 (81%), with six complete remissions (CR) and three partial remissions (PR); no severe toxicity was observed. The median PFS had lasted for quite 10 months with one maintaining for 25-month continuous CR. a big inverse correlation between the molecule levels of the CAR gene and disease recurrence or progression was observed. Additionally, it had been deservered to be addressed clinically that the lesions in some special sites like in spleen and testicle were refractory to CART-20 treatment.